Nijmegen, Netherlands and Neuried, Germany; May 6, 2014: Synthon Biopharmaceuticals BV and MAB Discovery GmbH today announced the execution of a research and license agreement. Under the terms of the agreement, MAB Discovery will generate antibodies for targets selected by Synthon in support of the company’s development of antibodydrug conjugates (ADCs) and alternative antibody-based therapeutics.
MAB Discovery will employ its in vivo antibody discovery technology platform, which relies on
the natural immune response of rabbits followed by state-of-the-art B-cell cloning techniques.
Using a novel high-throughput screening route, MAB Discovery focuses on identifying highly
active antibodies with unprecedented epitope coverage, potency and species cross-reactivity
which has been successful for intractable targets. This technology eliminates affinity maturation
and surrogate development which are very time-consuming and often sacrifice function.
Synthon will obtain high quality antibodies in support of their strategy to create a portfolio of
best-in-class antibody-based therapeutics, including ADCs.
Additional details of the transaction were not disclosed.
- ENDS -
Synthon, with headquarters in Nijmegen, The Netherlands, is an international pharmaceutical
company and a leader in the field of generic medicines. The company started its
biopharmaceutical franchise in 2007 and is building a promising portfolio of next generation
medicines. Synthon is developing rapidly into a specialty pharmaceutical company, focusing on
the therapeutic areas of auto-immune diseases and oncology. Synthon products are currently
approved by regulatory agencies in over 80 countries worldwide and marketed through strategic
partnerships and - in dedicated areas - through direct sales. Synthon employs about 1,400 staff
worldwide, and in 2013 it recorded a turnover of EUR 215 million. For more information, go to
About MAB Discovery
MAB Discovery was founded in Munich, Germany in October 2010. The team represents a
group of scientists out of Roche Biologicals R&D with extensive experience in developing
biologically based therapeutics. Funded by PPD Inc., MAB Discovery follows a collaborationbased
business model as a basis for its partnerships. Because of their unique funding situation,
MAB Discovery can employ flexible business models to meet the needs of their clients. For
more information, go to www.mabdiscovery.com.
For more information please contact:
Synthon: MAB Discovery:
Fabienne Douven Dr Birgit Zech
Director Corporate Communications Vice President Business Development
+31 24 372 7700 +49 89 990 178-0
For media inquiries:
MC Services AG
Phone: +49 89 210 228-30